Previous 10 | Next 10 |
home / stock / azncf / azncf news
2023-11-09 02:19:24 ET More on AstraZeneca AstraZeneca: Revenue Softening Possible, Profits To Rise AstraZeneca: Buy This Blue-Chip Bargain For A Richer Retirement AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity Earnings week ahead: Di...
2023-11-08 17:56:47 ET Summary BlackRock Enhanced International Dividend Trust provides exposure to international equities, with a focus on dividend-paying companies. BGY offers a discounted share price and is invested in discounted international markets, making it an appealing op...
2023-11-08 14:17:32 ET Summary AstraZeneca's upcoming results have the potential of turning around its 8% price decline YTD as profit growth can be sustained, making its forward multiples attractive again. The outlook on revenues is less buoyant, on the expected decline in sales o...
2023-11-07 17:07:59 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-11-04 11:35:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund declined 6.98% in Q3 2023, underperforming the benchma...
2023-11-03 18:57:50 ET Summary Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The company recently entered into a collaboration...
2023-11-02 09:00:00 ET Summary Pfizer's stock has dropped due to a decline in revenues post-COVID, presenting a value investment opportunity. The company still generates significant gross profit and has a strong revenue growth rate. Pfizer's low Price-to-Earnings ratio and imp...
2023-10-26 10:53:55 ET More on BioNTech, GSK, etc. Pfizer: Ignore The Noise And Buy This Deep Value Seagen's Acquisition: EU Approval And Potential Upside Pfizer: Huge Upside Potential And 5%+ Yield Pfizer, BioNTech post early-stage data for COVID-flu combo s...
2023-10-26 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 08:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...